Stockscreener 앱 받기
2.78
0.00%
0.00
시간 외 거래:
2.75
-0.03
-1.08%
전일 마감가:
$2.78
열려 있는:
$2.85
하루 거래량:
355.79K
Relative Volume:
1.15
시가총액:
$96.64M
수익:
$210.00K
순이익/손실:
$-10.12M
주가수익비율:
-9.1689
EPS:
-0.3032
순현금흐름:
$-7.12M
1주 성능:
+0.36%
1개월 성능:
-24.04%
6개월 성능:
+2.96%
1년 성능:
-17.63%
1일 변동 폭
$2.69
$2.87
1주일 범위
$2.62
$2.87
52주 변동 폭
$2.32
$5.4566
Anixa Biosciences Inc Stock (ANIX) Company Profile
명칭
Anixa Biosciences Inc
전화
408-708-9808
주소
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.78 | 96.64M | 210.00K | -10.12M | -7.12M | -0.3032 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-21 | 개시 | Maxim Group | Buy |
| 2022-12-23 | 개시 | Chardan Capital Markets | Buy |
| 2021-04-12 | 개시 | H.C. Wainwright | Buy |
Anixa Biosciences Inc 주식(ANIX)의 최신 뉴스
Form 4 Anixa Biosciences Inc For: 25 September By Investing.com - Investing.com Nigeria
Anixa Biosciences (NASDAQ:ANIX) Director Lewis Titterton Jr Purchases 49,036 Shares of Company Stock - MarketBeat
Director Titterton Lewis H jr Buys 49,036 Shares of Anixa Biosci - GuruFocus
Anixa Biosciences director Lewis Titterton Jr. buys $131,906 in stock - Investing.com
Form 4 Anixa Biosciences Inc For: 25 September - Investing.com India
At $2.69 a share, an Anixa Biosciences (ANIX) director buys stock, bringing his direct holdings to 1,046,003 shares. - stocktitan.net
H.C. Wainwright lowers Anixa Biosciences stock price target to $6 By Investing.com - Investing.com Australia
H.C. Wainwright lowers Anixa Biosciences stock price target to $6 - Investing.com
ANIX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright Maintains Anixa Biosciences(ANIX.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
HC Wainwright Has Lowered Expectations for Anixa Biosciences (NASDAQ:ANIX) Stock Price - MarketBeat
HC Wainwright & Co. maintains Buy rating on Anixa Biosciences, $6 price target - TradingView
Anixa Biosciences secures Australian patent for breast cancer vaccine - scanx.trade
Anixa advances ovarian cancer CAR-T trial to highest dose level - scanx.trade
Anixa Biosciences (ANIX) Secures Australian Patent for Breast Ca - GuruFocus
Anixa receives Australian patent for breast cancer vaccine By Investing.com - Investing.com Canada
Anixa receives Australian patent for breast cancer vaccine - Investing.com
Anixa secures exclusive patent for breast cance... - Pluang
Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040 - PR Newswire
Anixa Biosciences Inc (NASDAQ:ANIX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Anixa Biosciences adds UPenn oncologist to advisory board By Investing.com - Investing.com Nigeria
Anixa Biosciences Adds Penn Cancer Expert Carmen Guerra to Advisory Board - citybiz
Anixa Biosciences adds UPenn oncologist to advisory board - Investing.com
Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board - streetinsider.com
Anixa Biosciences (ANIX) CEO Amit Kumar Buys 3,000 Shares, Insider Ownership Rises to 665,000 Shares - GuruFocus
Anixa Biosciences CEO Amit Kumar buys $8,250 in ANIX common stock - Investing.com Nigeria
Anixa Biosciences director Lewis Titterton Jr. buys $27,300 in stock - Investing.com
Anixa Biosciences director Lewis Titterton Jr. buys $27,300 in stock By Investing.com - Investing.com Nigeria
Anixa Biosciences (NASDAQ: ANIX) CEO lifts stake to 665,000 shares - Stock Titan
Anixa Biosciences (ANIX) director buys 10,000 shares - stocktitan.net
Anixa Biosciences (ANIX) CEO Amit Kumar Buys 5,000 Shares, Insider Ownership Climbs to 662,000 - GuruFocus
Anixa Biosciences CEO Amit Kumar acquires $13,799 in stock By Investing.com - Investing.com Canada
Anixa Biosciences CEO Amit Kumar acquires $13,799 in stock - investing.com
Amit Kumar Acquires 5,000 Shares of Anixa Biosciences (NASDAQ:ANIX) Stock - marketbeat.com
Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - ACCESS Newswire
ANIX: Innovative cancer therapies advance in clinic, supported by strong partnerships and financial discipline - TradingView
Anixa Biosciences at H.C. Wainwright: two cancer bets advance By Investing.com - Investing.com Canada
Anixa Biosciences at H.C. Wainwright: two cancer bets advance - Investing.com India
Anixa Biosciences (ANIX) CEO lifts stake to 662,000 shares - Stock Titan
Anixa Biosciences Q3 Results: EPS beats estimate, sales flat - scanx.trade
Anixa Biosciences (NASDAQ:ANIX) Issues Quarterly Earnings Results - marketbeat.com
Anixa Biosciences Inc reports results for the quarter ended July 31Earnings Summary - TradingView
Anixa Biosciences highlights progress in breast cancer vaccine on Bloomberg TV this Saturday. - Pluang
A breast cancer survivor will discuss Anixa's vaccine on TV - Stock Titan
Anixa Biosciences Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Anixa Biosciences Inc. (ANIX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Anixa Biosciences Inc. (ANIX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026 - PR Newswire
Anixa Biosciences (ANIX) Projected to Post Earnings on Wednesday - MarketBeat
Anixa Biosciences (ANIX) Sheds 1.5% to $3.60 as Biotech Momentum CoolsVolume Breakout Ideas - siam.in
Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy - AOL.ca
Anixa Biosciences Inc (ANIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):